30.65 USD
↗ 0.45 (1.49%)AT CLOSE (11:59 AM EDT)
Quince Therapeutics, Inc. Common Stock
QNCXNASDAQ • USD
29.94
↘ 0.71 (2.33%)
POST MARKET (AS OF 07:49 PM EDT)
Post Market
AS OF 07:49 PM EDT
29.94
↘ 0.71 (2.33%)
Market: CLOSED
Quince Therapeutics, Inc. Common Stock (QNCX) trades at $30.75 per share. Our models show a "Buy" technical signal alongside a "Neutral" fundamental rating. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Aug 10, 2026.
Open?$30.00
High?$31.47
Low?$29.68
Prev. Close?$30.20
Volume?33.7K
Avg. Volume?61.3K
VWAP?$30.74
Rel. Volume?0.55x
Bid / Ask
Bid?$17.05 × 100
Ask?$31.77 × 100
Spread?$14.72
Midpoint?$24.41
Valuation & Ratios
Market Cap?30.0M
Shares Out?1.0M
Float?15.3M
Float %?93.7%
P/E Ratio?N/A
P/B Ratio?1.91
EPS?-$36.97
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
Employees
38
Market Cap
29.5M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2019-05-09
Address
611 GATEWAY BLVD., SUITE 273
SOUTH SAN FRANCISCO, CA 94080
Phone: 415-910-5717
SOUTH SAN FRANCISCO, CA 94080
Phone: 415-910-5717
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?100
Piotroski F-Score?0/9Weak
Altman Z-Score?-27.09Distress
Confidence?40%Low
Short InterestLow
Short % of Float?0.33%Low
Short Interest?50.6K
Days to Cover?1.2
Free Float15.3M
Avg Daily Volume42.8K
Settlement Date2026-07-15
Financial Health
Current Ratio?2.92Strong
Quick Ratio?2.92Strong
Cash Ratio?2.07Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.91CHEAP▾
Peers100
S&P76
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.2CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-230.7%WEAK▾
S&P3
ROA?-135.8%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-37731000
Enterprise Value?$11.8M
Fundamentals ratios updated end of day